Happy Earth Day! What terms should we be using to describe our current climate situation? Let’s decide.

A recent study reveals some alarming statistics about physician suicide. What interventions can help reduce this trend?

The first patient has been dosed in MindMed’s phase 3 Emerge study evaluating the efficacy of MM120 ODT.

2025: one of the most consequential years ever for emergency psychiatry.

The use of arts in psychiatry has been a healing and therapeutic tool of care, though unfortunately decimated over the years by cuts in funding.

Research has found a higher rate of female physician suicide. One of the investigators shares more details.

Here are highlights from this week in Psychiatric Times, including

About 40% of women who have postpartum depression go unrecognized and untreated, and they are still symptomatic 3 years later.

A retired psychiatrist has a conversation with AI about substance use disorder treatment.

"All morning I did the work I love. At noon I lay down with my mate. It might have been otherwise."

At this time of great importance for religion, we see an increase in political anxiety.

The Lancet Commission report on nonfatal self-harm identifies key challenges, causes, and more.

A pioneer in cognitive behavior therapy shares his thoughts on a 50-year-long career.

The arson attack on Pennsylvania Governor Shapiro might have happened for a number of reasons…

"Tell him I’m sorry I still owe him money..."

What are the psychological implications of Passover?

Dr Wilsa Charles Malveaux highlights the urgent need to address mental health in Black Maternal Health Week, especially for Black mothers and athletes.

How can psychiatric professionals and pharmacists best work together to improve patient care? One pharmacist shares his thoughts.

Different medications for different domains: new treatments are changing the way schizophrenia is managed.

Take a look at the differentiation between prodrome and attenuated psychosis, along with cognitive impairment associated with schizophrenia.

The Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) for treatment-resistant major depressive disorder has now demonstrated promise for reducing depressive symptoms of bipolar I disorder in an open-label feasibility and safety trial.

Professionally and personally, what do you think about choosing your own death?

Here's what patients should know about Cobenfy for the treatment of schizophrenia.